Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 315-328

  Sukhai, Mahadeo A ^a   Prabha, Swayam ^a   Hurren, Rose ^a   Rutledge, Angela C ^a   Lee, Anna Y ^b   Sriskanthadevan, Shrivani ^a   Sun, Hong ^a   Wang, Xiaoming ^a   Skrtic, Marko ^a   Seneviratne, Ayesh ^a   Cusimano, Maria ^a   Jhas, Bozhena ^a   Gronda, Marcela ^a   MacLean, Neil ^a   Cho, Eunice E ^a   Spagnuolo, Paul A ^a   Sharmeen, Sumaiya ^a   Gebbia, Marinella ^b   Urbanus, Malene ^b   Eppert, Kolja ^a   Dissanayake, Dilan ^a   Jonet, Alexia ^c   Dassonville Klimpt, Alexandra ^c   Li, Xiaoming ^a   Datti, Alessandro ^d,e   Ohashi, Pamela S ^a   Wrana, Jeff ^d   Rogers, Ian ^d   Sonnet, Pascal ^c   Ellis, William Y ^f   Corey, Seth J ^g   Eaves, Connie ^h   Minden, Mark D ^a   Wang, Jean C Y ^a,b   Dick, John E ^a   Nislow, Corey ^b   Giaever, Guri ^b   Schimmer, Aaron D ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF PERUGIA   (Italy)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MEFLOQUINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOGENESIS; CANCER STEM CELL; CELL DISRUPTION; CELL SIZE; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SELECTIVITY; ENANTIOMER; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HAPLOINSUFFICIENCY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYSOSOME; LYSOSOME DISRUPTION; LYSOSOME MEMBRANE; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTIMALARIALS; CELL SURVIVAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTRACELLULAR MEMBRANES; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MALE; MEFLOQUINE; MICE; NEOPLASTIC STEM CELLS; PERMEABILITY; SACCHAROMYCES CEREVISIAE;

EID: 84873848473     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64180     Document Type: Article

References (72)

1. Lowenberg B, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16(3): 872-881.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7): 730-737.
3. Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464): 645-648.
4. de Duve C. The lysosome turns fifty. Nat Cell Biol. 2005;7(9): 847-849.
5. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer. 2005; 5(11): 886-897.
6. Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007;8(8): 622-632.
7. Baiocchi RA, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011; 117(11): 2442-2451.
8. Belch A, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007;18(1): 116-121.
9. Cavo M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758): 2075-2085.
10. Bagshaw RD, Mahuran DJ, Callahan JW. A proteomic analysis of lysosomal integral membrane proteins reveals the diverse composition of the organelle. Mol Cell Proteomics. 2005;4(2): 133-143.
11. Bagshaw RD, Mahuran DJ, Callahan JW. Lysosomal membrane proteomics and biogenesis of lysosomes. Mol Neurobiol. 2005;32(1): 27-41.
12. Callahan JW, Bagshaw RD, Mahuran DJ. The integral membrane of lysosomes: its proteins and their roles in disease. J Proteomics. 2009;72(1): 23-33.
13. Brunk UT, Neuzil J, Eaton JW. Lysosomal involvement in apoptosis. Redox Rep. 2001;6(2): 91-97.
14. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene. 2004;23(16): 2881-2890.
15. Leist M, Jaattela M. Triggering of apoptosis by cathepsins. Cell Death Differ. 2001;8(4): 324-326.
16. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2(8): 589-598.
17. Turk B, et al. Apoptotic pathways: involvement of lysosomal proteases. Biol Chem. 2002;383(7-8): 1035-1044.
18. Sharmeen S, et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 2010;116(18): 3593-3603.
19. Iyamu E, Perdew H, Woods G. Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway. Biochem Pharmacol. 2009; 77(6): 1021-1028.
20. Martirosyan AR, Rahim-Bata R, Freeman AB, Clarke CD, Howard RL, Strobl JS. Differentiationinducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem Pharmacol. 2004;68(9): 1729-1738.
21. Sachlos E, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149(6): 1284-1297.
22. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10): 1167-1174.
23. Boudreau E, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol. 1993;44(3): 257-265.
24. Harinasuta T, Bunnag D, Wernsdorfer WH. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1983;61(2): 299-305.
25. Warner JK, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia. 2005; 19(10): 1794-1805.
26. Borisy AA, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A. 2003; 100(13): 7977-7982.
27. Chawira AN, Warhurst DC, Robinson BL, Peters W. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. Trans R Soc Trop Med Hyg. 1987;81(4): 554-558.
28. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985; 228(4703): 1049-1055.
29. Chang SP, Shen SC, Lee WR, Yang LL, Chen YC. Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells. J Dermatol Sci. 2011; 62(3): 183-191.
30. Hoebe KH, Monshouwer M, Witkamp RF, Fink- Gremmels J, van Miert AS. Cocultures of porcine hepatocytes and Kupffer cells as an improved in vitro model for the study of hepatotoxic compounds. Vet Q. 2000;22(1): 21-25.
31. Nakamura T, Lipton SA. Preventing Ca2+-mediat ed nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium. 2010;47(2): 190-197.
32. Thapa D, et al. Inhibitory effects of clotrimazole on TNF-alpha-induced adhesion molecule expression and angiogenesis. Arch Pharm Res. 2009; 32(4): 593-603.
33. Touzet O, Philips A. Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS. 2010;24(10): 1437-1447.
34. Zhang S, Chen H, Gerhard GS. Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. Chem Biol Interact. 2010;186(1): 30-35.
35. Hamacher-Brady A, et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem. 2010;286(8): 6587-6601.
36. Wu SJ, Ng LT, Lin CC. Effects of vitamin E on the cinnamaldehyde-induced apoptotic mechanism in human PLC/PRF/5 cells. Clin Exp Pharmacol Physiol. 2004;31(11): 770-776.
37. Giaever G, et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A. 2004; 101(3): 793-798.
38. Giaever G, et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet. 1999; 21(3): 278-283.
39. Hoon S, et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol. 2008;4(8): 498-506.
40. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43): 15545-15550.
41. Skrtic M, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20(5): 674-688.
42. Glaumann H, Motakefi AM, Jansson H. Intracellular distribution and effect of the antimalarial drug mefloquine on lysosomes of rat liver. Liver. 1992;12(4 pt 1): 183-190.
43. Johansson AC, Steen H, Ollinger K, Roberg K. Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by staurosporine. Cell Death Differ. 2003; 10(11): 1253-1259.
44. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006;281(17): 11923-11932.
45. Zhang H, Zhong C, Shi L, Guo Y, Fan Z. Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochondria through processing of bid leading to Necroptosis. J Immunol. 2009;182(11): 6993-7000.
46. Eberhard Y, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood. 2009;114(14): 3064-3073.
47. Karle JM, Olmeda R, Gerena L, Milhous WK. Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol. 1993; 76(4): 345-351.
48. Wallen L, Ericsson O, Wikstrom I, Hellgren U. Highperformance liquid chromatographic method for the enantioselective analysis of mefloquine in plasma and urine. J Chromatogr B Biomed Appl. 1994; 655(1): 153-157.
49. Mullie C, Jonet A, Desgrouas C, Taudon N, Sonnet P. Differences in anti-malarial activity of 4-aminoalcohol quinoline enantiomers and investigation of the presumed underlying mechanism of action. Malar J. 2012;11:65.
50. Fehrenbacher N, et al. Sensitization to the lysosomal cell death pathway by oncogene-induced downregulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 2008;68(16): 6623-6633.
51. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007;26(2): 313-324.
52. Thiele DL, Lipsky PE. The action of leucyl-leucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptidase I-mediated conversion to membranolytic products. J Exp Med. 1990;172(1): 183-194.
53. Thiele DL, Lipsky PE. Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. Proc Natl Acad Sci U S A. 1990;87(1): 83-87.
54. Sardiello M, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009; 325(5939): 473-477.
55. Eppert K, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9): 1086-1093.
56. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010;304(24): 2706-2715.
57. Kikushige Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6): 708-717.
58. Basano SA, Bianco A, Taylor WR, Olliaro P, Camargo LM. An in vivo test to assess mefloquine 25 mg/kg for the treatment of uncomplicated falciparum malaria in Rondonia, Brazil. Braz J Infect Dis. 2006; 10(4): 279-282.
59. Charles BG, et al. Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. Eur J Clin Pharmacol. 2007;63(3): 271-278.
60. Nevin RL. Pharmacokinetic considerations in the repositioning of mefloquine for treatment of progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg. 2012;114(8): 1204-1205.
61. Hu YL, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012; 72(7): 1773-1783.
62. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10(9): 1533-1541.
63. Bellodi C, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009; 119(5): 1109-1123.
64. Ding WX, et al. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther. 2009;8(7): 2036-2045.
65. Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquineinduced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol. 2010;12(5): 473-481.
66. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest. 2008;118(1): 79-88.
67. Fehrenbacher N, et al. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 2004;64(15): 5301-5310.
68. Ono K, Kim SO, Han J. Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor alpha-induced cell death. Mol Cell Biol. 2003;23(2): 665-676.
69. Palmieri M, et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet. 2011; 20(19): 3852-3866.
70. Pena-Llopis S, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011; 30(16): 3242-3258.
71. Settembre C, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036): 1429-1433.
72. Samudio I, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2009; 120(1): 142-156.